IP Intelligence › Patent Criticalities › Why a good invention still gets a Section 3 objection
Patent criticality
Why a good invention still gets a Section 3 objection
The examiner says my invention is not an invention at all. What now?
A section 3 objection is a subject-matter objection, and it is answered by evidence and framing rather than by arguing about the prior art. Each clause has its own test, and using the wrong one wastes the reply.
Clause by clause, the answers are different
3(d) - a new form of a known substance. The answer is data showing a significant difference in properties with regard to efficacy; for a medicine, therapeutic efficacy. Improved stability, flow or bioavailability is not by itself enough.
3(e) - a mere admixture producing only the aggregation of the properties of its components. The answer is evidence of synergy: an effect greater than the sum of the parts, demonstrated by comparison.
3(i) - a method of treatment. The answer is usually category: claim the device, the composition, the kit, the apparatus - not the method performed on a patient.
3(k) - a computer programme per se, an algorithm, a mathematical or business method. The answer is a demonstrated technical effect, expressed in terms of what improves in the machine or the system, not in terms of what the user gains commercially.
3(f) - a mere rearrangement of known devices each working independently in a known way. The answer is functional interaction: show that the components co-operate to produce something none of them produces alone.
What does not work
Asserting that the invention is useful. Asserting that other offices have granted it - Indian subject-matter law differs, particularly for business methods, where India has no as such qualifier at all. Re-writing a method claim as a system claim while leaving the substance identical: Indian decisions look through claim format to what is really being claimed.
Section 3 of the Patents Act 1970, clauses (a) to (p), and section 4.
Indian courts have emphasised substance over claim form when applying section 3(k), and have applied a strict reading of efficacy under section 3(d).
The revised CRI Guidelines notified on 29 July 2025 set out a step-wise assessment for section 3(k), with worked examples and specific treatment of AI, machine learning, blockchain and quantum computing.
Generate the comparative data before you file, not after the objection. Data created after the priority date can be filed, but data that was never generated cannot.
Treating a section 3 objection as boilerplate. It is often the objection that decides the case.
Objections that cite two or three clauses together. Each needs its own answer.
Identify which clause is actually being relied on, then ask what evidence that clause requires. That is the whole reply.
Sources & further reading
- Section 3, Patents Act 1970 - what are not inventions — Official IP India section text
- Revised Guidelines for Examination of Computer Related Inventions, notified 29 July 2025 — CGPDTM, via Press Information Bureau
- Novartis AG v Union of India, Supreme Court of India, 1 April 2013, (2013) 6 SCC 1
Related
Section 3(d)
A provision that treats a new form of a known substance as unpatentable unless it differs significantly in properties **with regard to efficacy**, and also bars the …
Section 3(k)
Section 3(k) excludes a mathematical method, a business method, a computer programme **per se**, and algorithms from being inventions.
The data you did not generate
In chemistry, biotechnology, pharmaceuticals and food technology, several of the objections you will face can only be answered with comparative data. If nobody gener…
The case that defined what "efficacy" means
The case that confirmed India bars business methods absolutely
Holding an examination report?
A reply is an argument, not a form. What you concede now shapes what your patent is worth later.
Educational guidance, not legal advice. This material is published by Ragulika IP for general education and information. It is not legal advice, it does not create a professional-client relationship, and it is not a substitute for advice on your own facts. Patentability, infringement, prosecution strategy and every other IP outcome turn on the specific facts and on the law and Patent Office practice as they stand at the time you act. Please take professional advice before making a decision, and read the underlying provision or judgment before relying on any point stated here.
Last reviewed by Ragulika IP on 2026-08-23. Indian patent law and Patent Office practice change; check the position before you rely on it.